Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role and evolution of therapeutic options.

Literature DB >> 8883132

Role and evolution of therapeutic options.

R W Keen¹, T D Spector.

Abstract

Mesh：

Substances：

Year: 1996 PMID： 8883132 DOI： 10.1007/bf01625237

Source DB: PubMed Journal: Osteoporos Int ISSN： 0937-941X Impact factor: 4.507

× No keyword cloud information.

27 in total

1. Prevention of postmenopausal bone loss by tiludronate.

Authors: J Y Reginster; M P Lecart; R Deroisy; N Sarlet; D Denis; D Ethgen; J Collette; P Franchimont
Journal: Lancet Date: 1989 Dec 23-30 Impact factor: 79.321

2. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors: B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal: N Engl J Med Date: 1990-03-22 Impact factor: 91.245

3. The effect of postmenopausal estrogen therapy on bone density in elderly women.

Authors: D T Felson; Y Zhang; M T Hannan; D P Kiel; P W Wilson; J J Anderson
Journal: N Engl J Med Date: 1993-10-14 Impact factor: 91.245

4. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245

5. Differences in proximal femur bone density over two centuries.

Authors: B Lees; T Molleson; T R Arnett; J C Stevenson
Journal: Lancet Date: 1993-03-13 Impact factor: 79.321

6. The incidence of hip fracture in Europe.

Authors: J A Kanis
Journal: Osteoporos Int Date: 1993 Impact factor: 4.507

7. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Authors: S T Harris; N B Watts; R D Jackson; H K Genant; R D Wasnich; P Ross; P D Miller; A A Licata; C H Chesnut
Journal: Am J Med Date: 1993-12 Impact factor: 4.965

8. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

Authors: K Overgaard; M A Hansen; S B Jensen; C Christiansen
Journal: BMJ Date: 1992-09-05